A recent study at at the Cleveland clinic compares 3 common prostate cancer treatments: external beam radiation, surgery and brachytherapy. Experts have found external beam radiation therapy to be more toxic and expensive than either surgery or brachytherapy.
The findings were to be presented Tuesday at a meeting in San Francisco, hosted in part by the American […]

continue reading from " Study Compares 3 Common Prostate Cancer Treatments "

Good news for men diagnosed with low-risk, localized prostate cancer. Results of a three-year international clinical trial show that being treated with the drug dutasteride (”Avodart”) delays disease progression and initiating active treatment, and also reduces anxiety.
Researchers say that using active surveillance plus dutasteride , patients can avoid aggressive treatment that can have a major […]

continue reading from " Dutasteride delays prostate cancer progression, Study "

Urologists say many prostate cancer patients develop bone metastases, and controlling the pain these cause can be difficult. Now the first large randomised Phase III trial of a bisphosphonate drug in these patients has shown that a single dose of the drug is as good for pain relief as single dose radiotherapy, the standard treatment […]

continue reading from " Bone-strengthening drug gives pain relief in prostate cancer bone metastases "

According to results from a phase III clinical trial at the San Camillo and Forlanini Hospitals in Rome, Italy, men with prostate cancer that has spread to other parts of the body and that is resistant to hormone therapy suffer less from fatigue if they are treated with a combination of abiraterone acetate and prednisone. […]

continue reading from " Abiraterone acetate improves fatigue in prostate cancer patients "

For patients whose cancer returned after radiation treatment a new technique may be able to remove prostate cancer in patients without any incisions.
The treatment is called High Intensity Focused Ultrasound, or HIFU, and uses ultrasound energy, sound waves, to quickly heat tissue to destroy cancer cells. The energy for this is directed by an ultrasound […]

continue reading from " HIFU: new treatment option for men with recurrent prostate cancer "

Prostate cancer, the most common form of cancer in U.S. men, is also one of the most treatable: According to the journal Seminars in Radiation Oncology, 90 percent of patients who undergo intensity modulated radiation therapy (IMRT) in the early stages are disease free after five years. So, in less than a decade, IMRT  has […]

continue reading from " IMRT a common and successful prostate cancer treatment "

A sudy at the Dana-Farber/Brigham found that by five years, 31.8 percent of the men who received hormones had died compared to 19.5 percent of the men who did not receive hormone therapy. In conclusion, researchers say adding hormone therapy to treat prostate cancer may reduce overall survival in men with pre-existing heart conditions. The […]

continue reading from " Adding hormone therapy led to a significant increase in overall mortality. "

Digoxin alters enzymatic pathways for sodium and potassium in heart cells that slows the heart rate while improving pumping action. Recently, a robotic surgery expert who is also a urologic oncologist, said that Digoxin could potentially do the same for prostate cancer.
According to a study by scientists at Johns Hopkins men who used this cardiac drug had a 24 percent […]

continue reading from " Regular Digoxin users had a 24% lower risk of prostate cancer "

Androgen-deprivation therapy (ADT) is a hormone therapy that deprives the patient’s body of androgens, such as testosterone, which have been shown to stimulate the growth of prostate cancer cells
Despite its clinical efficacy in advanced prostate cancer, ADT is associated with an array of adverse side-effects such as insulin resistance and increased risk of cardiovascular disease. […]

continue reading from " Androgen-deprivation therapy is associated with an array of adverse side-effects "

Researchers from VTT Technical Research Centre of Finland and the University of Turku have demonstrated that an antibiotic called “monensin” prevents the growth of prostate cancer cells.
 Researchers found that small amounts of compounds — disulfiram (Antabus), thiram, tricostatin A, and monensin — can prevent the growth of prostate cancer cells without significant effects on the […]

continue reading from " Researchers identified compound that prevents the growth of prostate cancer cells "